XNAS
TVGNW
Market cap24mUSD
Oct 30, Last price
0.09USD
1D
18.24%
1Q
91.05%
IPO
-7.89%
Name
Tevogen Bio Holdings Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing ready-to-use, precision T cell therapies. Their research and development efforts span virology, oncology, and neurological conditions. The company's flagship experimental treatment, TVGN 489, is a precision T cell product designed to meet the unmet needs of individuals severely affected by acute COVID-19, as well as a specific group of patients struggling with long COVID. Tevogen Bio Holdings Inc. is headquartered in Warren, New Jersey.
Key people
Ryan Saadi
Chairman of the Board, Chief Executive Officer · since 2024
Kirti Desai
Chief Financial Officer · since 2024
Neal Flomenberg
Chief Scientific Officer and Global R&D Lead · since 2024
Sadiq Khan
Chief Commercial Officer
Jeffrey Feike
Independent Director Nominee
Keow Lin Goh
Independent Director Nominee
Curtis Patton
Independent Director Nominee
Independent Director · since 2024
Victor Sordillo
Independent Director Nominee
Legal address
C/O Maples Corporate Services Limited
PO Box 309, Ugland House
Grand Cayman
George Town KY1- 1104
KY
PO Box 309, Ugland House
Grand Cayman
George Town KY1- 1104
KY
Headquarters
767 Third Avenue
38th Floor
New York, NY 10017
US
38th Floor
New York, NY 10017
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||